cefepime

Known as: Cefepima, cefepim, cefepime [Chemical/Ingredient] 
A semisynthetic, broad-spectrum, fourth-generation cephalosporin with antibacterial activity. Cefepime binds to and inactivates penicillin-binding… (More)
National Institutes of Health

Related topics

Related topics

30 relations
Acinetobacter InfectionsBacterial InfectionsBone Diseases, InfectiousCefepime Islt KB
(More)

Broader (1)

Anti-Bacterial Agents

Narrower (3)

BMY 28142MaxipimeQuadrocef

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
The objective of this study was to evaluate the relationship of the predicted pharmacodynamic parameters 24-h area under the… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Community-associated Methicillin-resistant Staphylococcus aureus, Canada
A total of 184 methicillin-resistant Staphylococcus aureus (MRSA) strains were collected from patients who sought treatment… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
In a randomized, evaluator-blind, multicenter trial, we compared cefepime (2 g three times a day) with imipenem-cilastatin (500… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Pharmacodynamics of cefepime in patients with Gram-negative infections.
We conducted a prospective, open-label study to delineate a relationship between exposure and outcomes in 36 patients treated… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.
Therapeutic options for infections caused by gram-negative organisms expressing plasmid-mediated AmpC beta-lactamases are limited… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
There is little information about the clinical effectiveness of cefepime and piperacillin-tazobactam in the treatment of… (More)
Is this relevant?
2000
2000
Status epilepticus associated with cefepime.
Cefepime is a fourth-generation cephalosporin widely used for gram-negative sepsis. The authors report two patients in whom… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
Pseudomonas aeruginosa COL-1 was identified in a blood culture of a 39-year-old-woman treated with imipenem in Marseilles, France… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate.
Production of a metallo-beta-lactamase activity was detected in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Review
1993
Review
1993
Cefepime: the next generation?
Cefepime is a new aminothiazolylacetamido cephalosporin with a wider spectrum and greater potency than many currently available… (More)
Is this relevant?